Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B
Alexandre Kauskot, … , Cécile V. Denis, Dominique Baruch
Alexandre Kauskot, … , Cécile V. Denis, Dominique Baruch
Published October 6, 2016
Citation Information: JCI Insight. 2016;1(16):e88643. https://doi.org/10.1172/jci.insight.88643.
View: Text | PDF
Research Article Hematology

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B

  • Text
  • PDF
Abstract

von Willebrand disease type 2B (VWD-type 2B) is characterized by gain-of-function mutations of von Willebrand factor (vWF) that enhance its binding to platelet glycoprotein Ibα and alter the protein’s multimeric structure. Patients with VWD-type 2B display variable extents of bleeding associated with macrothrombocytopenia and sometimes with thrombopathy. Here, we addressed the molecular mechanism underlying the severe macrothrombocytopenia both in a knockin murine model for VWD-type 2B by introducing the p.V1316M mutation in the murine Vwf gene and in a patient bearing this mutation. We provide evidence of a profound defect in megakaryocyte (MK) function since: (a) the extent of proplatelet formation was drastically decreased in 2B MKs, with thick proplatelet extensions and large swellings; and (b) 2B MKs presented actin disorganization that was controlled by upregulation of the RhoA/LIM kinase (LIMK)/cofilin pathway. In vitro and in vivo inhibition of the LIMK/cofilin signaling pathway rescued actin turnover and restored normal proplatelet formation, platelet count, and platelet size. These data indicate, to our knowledge for the first time, that the severe macrothrombocytopenia in VWD-type 2B p.V1316M is due to an MK dysfunction that originates from a constitutive activation of the RhoA/LIMK/cofilin pathway and actin disorganization. This suggests a potentially new function of vWF during platelet formation that involves regulation of actin dynamics.

Authors

Alexandre Kauskot, Sonia Poirault-Chassac, Frédéric Adam, Vincent Muczynski, Gabriel Aymé, Caterina Casari, Jean-Claude Bordet, Christelle Soukaseum, Chantal Rothschild, Valérie Proulle, Audrey Pietrzyk-Nivau, Eliane Berrou, Olivier D. Christophe, Jean-Philippe Rosa, Peter J. Lenting, Marijke Bryckaert, Cécile V. Denis, Dominique Baruch

×

Figure 3

Type 2B mutant vWF/p.V1316M (2B) mice display abnormal megakaryocyte morphology with a decreased demarcation membrane system (DMS).

Options: View larger image (or click on image) Download as PowerPoint
Type 2B mutant vWF/p.V1316M (2B) mice display abnormal megakaryocyte mor...
(A) Representative image of the bone marrow after toluidine blue staining. Megakaryocytes (MKs) are identified with red asterisks. Scale bars: 40 μm. (B) Image of myelogram of the bone marrow. Bone marrow was spread on a coverslip and then stained with H&E. Scale bars: 30 μm. (C) Transmission electron microscopy of stage III MKs in the bone marrow in WT and 2B mice at 2 magnifications. Scale bars: 2 μm (top) and 1 μm (bottom). White squares indicate the magnification zone. n = 4. (D) Images of the threshold (ImageJ software [NIH], in red) in the central zone of MKs used to quantify the area of the DMS in WT (left) and 2B MKs (right) at stage III. Quantification of the area of the DMS of 13 MKs in each group. Statistical significance was determined by Student’s t test. ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts